BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 14766247)

  • 1. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression.
    Jazaeri AA; Nunes KJ; Dalton MS; Xu M; Shupnik MA; Rice LW
    Oncogene; 2001 Oct; 20(47):6965-9. PubMed ID: 11687977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of estrogen receptors alpha and beta, and progesterone receptors A and B in human mucinous carcinoma of the endometrium.
    Shabani N; Mylonas I; Jeschke U; Thaqi A; Kuhn C; Puchner T; Friese K
    Anticancer Res; 2007; 27(4A):2027-33. PubMed ID: 17649817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein kinase C alpha expression is inversely related to ER status in endometrial carcinoma: possible role in AP-1-mediated proliferation of ER-negative endometrial cancer.
    Fournier DB; Chisamore M; Lurain JR; Rademaker AW; Jordan VC; Tonetti DA
    Gynecol Oncol; 2001 Jun; 81(3):366-72. PubMed ID: 11371124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
    Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
    Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
    Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
    Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal and malignant human endometrium express immunohistochemically estrogen receptor alpha (ER-alpha), estrogen receptor beta (ER-beta) and progesterone receptor (PR).
    Mylonas I; Jeschke U; Shabani N; Kuhn C; Kriegel S; Kupka MS; Friese K
    Anticancer Res; 2005; 25(3A):1679-86. PubMed ID: 16033082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
    Singh M; Zaino RJ; Filiaci VJ; Leslie KK
    Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
    Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
    Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
    Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
    Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial and stromal estrogen and progesterone receptor expression in endometrial cancer: true color computer-assisted image analysis versus subjective scoring.
    Kohlberger PD; Kieback DG; Breitenecker F; Loesch A; Gitsch G; Kainz C; Breitenecker G
    Gynecol Oncol; 1997 Mar; 64(3):404-10. PubMed ID: 9062141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
    Henriksen KL; Rasmussen BB; Lykkesfeldt AE; Møller S; Ejlertsen B; Mouridsen HT
    Acta Oncol; 2009; 48(4):522-31. PubMed ID: 19173092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer.
    Takama F; Kanuma T; Wang D; Kagami I; Mizunuma H
    Br J Cancer; 2001 Feb; 84(4):545-9. PubMed ID: 11207052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.